Analysis of adherence to statin therapy among children with familial hypercholesterolemia: results of a 3-year prospective study
- Authors: Sadykova D.I1, Galimova L.F1,2, Slastnikova E.S1,2, Usova N.E2, Khaliullina C.D1
-
Affiliations:
- Kazan State Medical University
- Children's Republican Clinical Hospital, Kazan
- Issue: Vol 28, No 1 (2021)
- Pages: 81-85
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/313062
- DOI: https://doi.org/10.18565/pharmateca.2021.1.81-85
- ID: 313062
Cite item
Abstract
Full Text
About the authors
D. I Sadykova
Kazan State Medical University
Email: sadykovadi@mail.ru
Dr. Sci. (Med.), Head of the Department of Hospital Pediatrics
L. F Galimova
Kazan State Medical University; Children's Republican Clinical Hospital, Kazan
E. S Slastnikova
Kazan State Medical University; Children's Republican Clinical Hospital, Kazan
N. E Usova
Children's Republican Clinical Hospital, Kazan
Ch. D Khaliullina
Kazan State Medical University
References
- Duerden M., O'Flynn N., Qureshi N. Cardiovascular risk assessment and lipid modification: NICE guideline. Br J. Gen Pract. 2015;65(636):378-80. doi: 10.3399/bjgp15X685933.
- Mendis S., Puska P., Norrving B. Global atlas on cardiovascular disease prevention and control. Geneva: World Health Organization, 2011.
- Mozaffarian D., Benjamin E.J., Go A.S., et al. Heart disease and stroke statistics - 2016 update: a report from the American Heart Association. Circulation. 2016;133(4):e38-60. Doi: 10.1161/ CIR.0000000000000350.
- Ebrahim S., Taylor F.C., Brindle P. Statins for the primary prevention of cardiovascular disease. BMJ. 2014;348:g280. doi: 10.1136/bmj.g280.
- Gu Q., Paulose-Ram R., Burt V.L., et al. Prescription cholesterol-lowering medication use in adults aged 40 and over: United States, 2003-2012. NCHS Data Brief. 2014;(177):1-8.
- Fulcher J., O'Connell R., Voysey M., et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015;385(9976):1397-405. doi: 10.1016/S0140-6736(14)61368-4.
- Mihaylova B., Emberson J., Blackwell L., et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: metaanalysis of individual data from 27 randomised trials. Lancet. 2012;380(9841):581-90. doi: 10.1016/S0140-6736(12)60367-5.
- Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170000 participants in 26 randomised trials. Lancet. 2010;376:1670-81. Doi: 10.1016/ S0140-6736(10)61350-5.
- Di Angelantonio E., Sarwar N., Perry P., et al. Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;11;302(18):1993-2000. doi: 10.1001/jama.2009.1619.
- Клинические рекомендации. Семейная гипер-холестеринемия. 2018 г. Электронный источник. [Clinical guidelines. Familial hypercholesterolemia. 2018 Electronic source. (In Russ.)]. URL: https:// noatero.ru/sites/default/files/proekt_klinicheskie_ rekomendacii_sghs_mz_rf_18.01.pdf.
- Ference B.A., Ginsberg H.N., Graham I., et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459-72. doi: 10.1093/eurheartj/ ehx144.
- Grundy S.M., Arai H., Barter P, et al. An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia - full report. J Clin Lipidol. 2014;8:29 60. doi: 10.1016/j.jacl.2013.12.005
- Luirink I.K., Wiegman A., Kusters D.M., et al. 20-Year Follow-up of Statins in Children with Familial Hypercholesterolemia. N. Engl J. Med. 2019;381(16):1547-56. Doi: 10.1056/ nejmoa1816454.
- Wiegman A., Gidding S.S., Watts G.F., et al. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J. 2015;36(36):2425-37. doi: 10.1093/eurheartj/ehv157.
- Mach F., Baigent C., Catapano A.I., et al. ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2019;00:1-78. doi: 10.1093/eurheartj/ ehz455.
- Neil H.A., Hammond T., Huxley R., et al. Extent of underdiagnosis of familial hypercholesterolaemia in routine practice: prospective registry study. BMJ. 2000;15;321(7254):148. Doi: 10.1136/ bmj.321.7254.148.
- Ramaswami U., Futema M., Bogsrud M.P., et al. Comparison of the characteristics at diagnosis and treatment of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries. Atherosclerosis. 2020; 1(292)178-87. Doi: https://doi.org/10.1016/j. atherosclerosis.2019.11.012.